{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:58:54Z","timestamp":1781193534714,"version":"3.54.1"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.neuropharm.2025.110782","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T15:57:58Z","timestamp":1764086278000},"page":"110782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["An industrial perspective on ligand bias in GPCR drug discovery"],"prefix":"10.1016","volume":"284","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-9299","authenticated-orcid":false,"given":"James P.","family":"Farmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Holliday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Briddon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4469-0600","authenticated-orcid":false,"given":"Leigh A.","family":"Stoddart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110782_bib1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bcp.2017.03.014","article-title":"Capadenoson, a clinically trialed partial adenosine A1 receptor agonist, can stimulate adenosine A2B receptor biased agonism","volume":"135","author":"Baltos","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"5449","key":"10.1016\/j.neuropharm.2025.110782_bib2","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking \u03b2-arrestin 2","volume":"286","author":"Bohn","year":"1999","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110782_bib3","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1074\/jbc.M111.277178","article-title":"Functional selective oxytocin-derived agonists discriminate between individual G protein family subtypes","volume":"287","author":"Busnelli","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110782_bib4","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.3c00849","article-title":"Design, synthesis, and application of fluorescent ligands targeting the intracellular allosteric binding site of the CXC chemokine receptor 2","author":"Casella","year":"2023","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.neuropharm.2025.110782_bib5","doi-asserted-by":"crossref","DOI":"10.1021\/jm4010829","article-title":"Structure-activity relationships and discovery of a g protein biased \u03bc opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9 r)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain","volume":"56","author":"Chen","year":"2013","journal-title":"J. Med. Chem."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2025.110782_bib6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2008.07.040","article-title":"Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq\/11 activation and calcium mobilisation in CHO cells","volume":"594","author":"Cussac","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110782_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1021\/acsmedchemlett.5b00448","article-title":"Identification and preclinical pharmacology of BMS-986104: a differentiated S1P1 receptor modulator in clinical trials","volume":"7","author":"Dhar","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110782_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071980","article-title":"The \u03b2-blocker nebivolol is a GRK\/\u03b2-arrestin biased agonist","volume":"8","author":"Erickson","year":"2013","journal-title":"PLoS One"},{"issue":"625","key":"10.1016\/j.neuropharm.2025.110782_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci. Signal."},{"issue":"21","key":"10.1016\/j.neuropharm.2025.110782_bib11","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2000712117","article-title":"Biased signaling by endogenous opioid peptides","volume":"117","author":"Gomes","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"16","key":"10.1016\/j.neuropharm.2025.110782_bib12","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1016\/j.cell.2025.04.038","article-title":"Arrestin-biased allosteric modulator of neurotensin receptor 1 alleviates acute and chronic pain","volume":"188","author":"Guo","year":"2025","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110782_bib13","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41591-023-02381-w","article-title":"Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials","volume":"29","author":"Haney","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2025.110782_bib14","article-title":"The role of kinetic context in apparent biased agonism at GPCRs","volume":"7","author":"Herenbrink","year":"2016","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.neuropharm.2025.110782_bib15","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1111\/bph.14224","article-title":"The novel \u03bc\u2010opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception","volume":"175","author":"Hill","year":"2018","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110782_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/dom.15288","article-title":"Abolishing \u03b2-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists","volume":"26","author":"Hinds","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"issue":"552","key":"10.1016\/j.neuropharm.2025.110782_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat2214","article-title":"Biased antagonism of CXCR4 avoids antagonist tolerance","volume":"11","author":"Hitchinson","year":"2018","journal-title":"Sci. Signal."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110782_bib18","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/FJC.0000000000000356","article-title":"G protein-coupled receptor biased agonism","volume":"67","author":"Hodavance","year":"2016","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110782_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/bph.70109","article-title":"Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs","author":"Ippolito","year":"2025","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110782_bib20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cpdd.721","article-title":"A first-in-human clinical study with TRV734, an orally bioavailable G-Protein\u2013Biased ligand at the \u03bc-Opioid receptor","volume":"9","author":"James","year":"2020","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"10.1016\/j.neuropharm.2025.110782_bib21","author":"Jarpe"},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110782_bib22","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1021\/acschemneuro.0c00078","article-title":"An agonist dependent allosteric antagonist of prostaglandin EP2 receptors","volume":"11","author":"Jiang","year":"2020","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110782_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat. Commun."},{"issue":"18","key":"10.1016\/j.neuropharm.2025.110782_bib24","doi-asserted-by":"crossref","first-page":"11537","DOI":"10.1074\/jbc.M114.559542","article-title":"Convergence of melatonin and serotonin (5-HT) signaling at MT2\/5-HT2C receptor heteromers","volume":"290","author":"Kamal","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110782_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/S0165-6147(00)89032-X","article-title":"Agonist-receptor efficacy II: agonist trafficking of receptor signals","volume":"16","author":"Kenakin","year":"1995","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110782_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/pr.118.016790","article-title":"Biased receptor signaling in drug discovery","volume":"71","author":"Kenakin","year":"2019","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110782_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/S0026-895X(25)10934-6","article-title":"Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists","volume":"35","author":"Kenakin","year":"1989","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110782_bib28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1124\/jpet.301.3.1179","article-title":"Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs","volume":"301","author":"Kilts","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"38","key":"10.1016\/j.neuropharm.2025.110782_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0804745105","article-title":"\u03b2-Blockers alprenolol and carvedilol stimulate \u03b2-arrestin-mediated EGFR transactivation","volume":"105","author":"Kim","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"13","key":"10.1016\/j.neuropharm.2025.110782_bib30","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/bph.15004","article-title":"Morphine-induced respiratory depression is independent of \u03b2-arrestin2 signalling","volume":"177","author":"Kliewer","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110782_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased \u03bc-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects","volume":"10","author":"Kliewer","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110782_bib32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jpain.2023.02.116","article-title":"G protein-biased Mu opioid receptor agonist SR-17018 has low in vivo efficacy in non-human Primates","volume":"24","author":"Ko","year":"2023","journal-title":"J. Pain"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110782_bib33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacl.2008.08.445","article-title":"Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans","volume":"2","author":"Lai","year":"2008","journal-title":"Journal of Clinical Lipidology"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110782_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/mol.117.109355","article-title":"Slowly signaling G protein-biased CB2 cannabinoid receptor agonist LY2828360 suppresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence","volume":"93","author":"Lin","year":"2018","journal-title":"Mol. Pharmacol."},{"issue":"7668","key":"10.1016\/j.neuropharm.2025.110782_bib35","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature23652","article-title":"Mechanism of intracellular allosteric \u03b22AR antagonist revealed by X-ray crystal structure","volume":"548","author":"Liu","year":"2017","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110782_bib36","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1021\/acschembio.9b00533","article-title":"A biased agonist at immunometabolic receptor GPR84 causes distinct functional effects in macrophages","volume":"14","author":"Lucy","year":"2019","journal-title":"ACS Chem. Biol."},{"issue":"7619","key":"10.1016\/j.neuropharm.2025.110782_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2025.110782_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.687489","article-title":"Differential regulation of GPCRs\u2014Are GRK expression levels the key?","volume":"9","author":"Matthees","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110782_bib39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/mol.117.110890","article-title":"Biased agonism in drug discovery-is it too soon to choose a path?","volume":"93","author":"Michel","year":"2018","journal-title":"Mol. Pharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110782_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2013.06.006","article-title":"Activation of MAPK by inverse agonists in six naturally occurring constitutively active mutant human melanocortin-4 receptors","volume":"1832","author":"Mo","year":"2013","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"issue":"0","key":"10.1016\/j.neuropharm.2025.110782_bib41","article-title":"GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity","volume":"0","author":"Motso","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2025.110782_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metabol."},{"issue":"JUN","key":"10.1016\/j.neuropharm.2025.110782_bib43","article-title":"Desensitization of cAMP accumulation via human \u03b23-adrenoceptors expressed in human embryonic kidney cells by full, partial, and biased agonists","volume":"10","author":"Okeke","year":"2019","journal-title":"Front. Pharmacol."},{"issue":"30","key":"10.1016\/j.neuropharm.2025.110782_bib44","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/eurheartj\/ehx196","article-title":"Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)","volume":"38","author":"Pang","year":"2017","journal-title":"Eur. Heart J."},{"issue":"30","key":"10.1016\/j.neuropharm.2025.110782_bib45","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/eurheartj\/ehx196","article-title":"Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)","volume":"38","author":"Pang","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.neuropharm.2025.110782_bib46","series-title":"Pfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron","year":"2025"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110782_bib47","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1124\/mol.117.109678","article-title":"Teaching an old drug new tricks: agonism, antagonism, and biased signaling of pilocarpine through M3 muscarinic acetylcholine receptor","volume":"92","author":"Pronin","year":"2017","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110782_bib48","article-title":"Ligand-directed biased agonism at human histamine H3 receptor isoforms across G\u03b1i\/o- and \u03b2-arrestin2-mediated pathways","author":"Rahman","year":"2023","journal-title":"Biochem. Pharmacol."},{"issue":"17","key":"10.1016\/j.neuropharm.2025.110782_bib49","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1073\/pnas.1201093109","article-title":"Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy","volume":"109","author":"Rahmeh","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"17","key":"10.1016\/j.neuropharm.2025.110782_bib50","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1201093109","article-title":"Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy","volume":"109","author":"Rahmeh","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110782_bib51","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1073\/pnas.0912852107","article-title":"\u03b2-arrestin- but not G protein-mediated signaling by the \u201cdecoy\u201d receptor CXCR7","volume":"107","author":"Rajagopal","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.neuropharm.2025.110782_bib52","first-page":"356","article-title":"The structure and function of G-protein-coupled receptors","volume":"459","author":"Rosenbaum","year":"2009","journal-title":"Nature 2009"},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110782_bib53","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1021\/acs.jcim.1c00317","article-title":"BiasNet: a model to predict ligand bias toward GPCR signaling","volume":"61","author":"Sanchez","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.neuropharm.2025.110782_bib54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cellsig.2017.01.016","article-title":"Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor","volume":"32","author":"Schattauer","year":"2017","journal-title":"Cell. Signal."},{"issue":"50","key":"10.1016\/j.neuropharm.2025.110782_bib55","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M112.381368","article-title":"Ligand directed signaling differences between rodent and human \u03ba-opioid receptors","volume":"287","author":"Schattauer","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"50","key":"10.1016\/j.neuropharm.2025.110782_bib56","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M112.381368","article-title":"Ligand directed signaling differences between rodent and human \u03ba-opioid receptors","volume":"287","author":"Schattauer","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2025.110782_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173443","article-title":"Tolerance develops toward GLP-1 receptor agonists' glucose-lowering effect in mice","volume":"885","author":"Sedman","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110782_bib58","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2019.05.006","article-title":"Biased signaling of G protein coupled receptors (GPCRs): molecular determinants of GPCR\/transducer selectivity and therapeutic potential","volume":"200","author":"Seyedabadi","year":"2019","journal-title":"Pharmacol. Therapeut."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110782_bib59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrd.2018.180","article-title":"GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures","volume":"18","author":"Shimada","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110782_bib60","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.chembiol.2020.06.006","article-title":"Monitoring allosteric interactions with CXCR4 using NanoBiT conjugated nanobodies","volume":"27","author":"Soave","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110782_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.207","article-title":"First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"54","author":"Soergel","year":"2014","journal-title":"J. Clin. Pharmacol."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110782_bib62","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jcph.111","article-title":"First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"53","author":"Soergel","year":"2013","journal-title":"J. Clin. Pharmacol."},{"issue":"48","key":"10.1016\/j.neuropharm.2025.110782_bib63","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2102178118","article-title":"G protein signaling\u2013biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists","volume":"118","author":"Stahl","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110782_bib64","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1021\/cb900276p","article-title":"Detection of novel functional selectivity at M3 muscarinic acetylcholine receptors using a Saccharomyces cerevisiae platform","volume":"5","author":"Stewart","year":"2010","journal-title":"ACS Chem. Biol."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110782_bib65","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41422-025-01095-7","article-title":"Molecular mechanism of the arrestin-biased agonism of neurotensin receptor 1 by an intracellular allosteric modulator","volume":"35","author":"Sun","year":"2025","journal-title":"Cell Res."},{"issue":"21","key":"10.1016\/j.neuropharm.2025.110782_bib66","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1111\/bph.12620","article-title":"Investigating the molecular mechanisms through which FTY720-P causes persistent S1P1 receptor internalization","volume":"171","author":"Sykes","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110782_bib67","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2147\/JPR.S278279","article-title":"Oliceridine: a novel drug for the management of moderate to severe acute pain \u2013 a review of current evidence","volume":"14","author":"Tan","year":"2021","journal-title":"J. Pain Res."},{"key":"10.1016\/j.neuropharm.2025.110782_bib68","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2337\/db13-0893","article-title":"Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia","volume":"63","author":"Umapathysivam","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.neuropharm.2025.110782_bib69","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bcp.2018.10.015","article-title":"CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry","volume":"158","author":"Van Hout","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110782_bib70","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-022-01507-x","article-title":"Essential role of P-glycoprotein in the mechanism of action of oliceridine","volume":"48","author":"Ventriglia","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110782_bib71","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.110.173005","article-title":"Selectively engaging \u03b2-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance","volume":"335","author":"Violin","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110782_bib72","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.110.173005","article-title":"Selectively engaging \u03b2-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance","volume":"335","author":"Violin","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"26","key":"10.1016\/j.neuropharm.2025.110782_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202200269","article-title":"Structure-based evolution of G protein-biased \u03bc-Opioid receptor agonists","volume":"61","author":"Wang","year":"2022","journal-title":"Angew. Chem., Int. Ed."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110782_bib74","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/cvr\/cvaa266","article-title":"Carvedilol induces biased \u03b21 adrenergic receptor-nitric oxide synthase 3-cyclic guanylyl monophosphate signalling to promote cardiac contractility","volume":"117","author":"Wang","year":"2020","journal-title":"Cardiovasc. Res."},{"issue":"5\u20137","key":"10.1016\/j.neuropharm.2025.110782_bib75","first-page":"841","article-title":"Crystal structures of a stabilized \u03b21-Adrenoceptor bound to the biased agonists bucindolol and carvedilol","volume":"20\u2013540","author":"Warne","year":"2012","journal-title":"Structure(London, England:1993)"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110782_bib76","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/pm\/pnz122","article-title":"Dilemma of addiction and respiratory depression in the treatment of pain: a prototypical endomorphin as a new approach","volume":"21","author":"Webster","year":"2020","journal-title":"Pain Med."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110782_bib77","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cell.2018.12.005","article-title":"Angiotensin analogs with divergent bias stabilize distinct receptor conformations","volume":"176","author":"Wingler","year":"2019","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110782_bib78","doi-asserted-by":"crossref","DOI":"10.1111\/bph.13441","article-title":"Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased \u03bc opioid receptor agonists","volume":"173","author":"Winpenny","year":"2016","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110782_bib79","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1021\/acs.chemrev.6b00049","article-title":"Allostery and biased agonism at class B G protein-coupled receptors","volume":"117","author":"Wootten","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.neuropharm.2025.110782_bib80","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41589-021-00930-3","article-title":"Structural basis of sphingosine-1-phosphate receptor 1 activation and biased agonism","volume":"18","author":"Xu","year":"2021","journal-title":"Nat. Chem. Biol."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110782_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2016.05.008","article-title":"Biased signaling initiated by agouti-related peptide through human melanocortin-3 and -4 receptors","volume":"1862","author":"Yang","year":"2016","journal-title":"Biochim. Biophys. Acta (BBA) - Mol. Basis Dis."},{"key":"10.1016\/j.neuropharm.2025.110782_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114001","article-title":"Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors","volume":"177","author":"Yuliantie","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110782_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114001","article-title":"Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors","volume":"177","author":"Yuliantie","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110782_bib84","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.01680","article-title":"Desmetramadol is identified as a G-protein biased \u03bc opioid receptor agonist","volume":"10","author":"Zebala","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"7790","key":"10.1016\/j.neuropharm.2025.110782_bib85","first-page":"432","article-title":"Activation of the GLP-1 receptor by a non-peptidic agonist","volume":"577","author":"Zhao","year":"2020","journal-title":"Nature 2020"},{"issue":"MAY","key":"10.1016\/j.neuropharm.2025.110782_bib86","article-title":"Biased signaling of protease-activated receptors","volume":"5","author":"Zhao","year":"2014","journal-title":"Front. Endocrinol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825004903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:17:59Z","timestamp":1781191079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825004903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":85,"alternative-id":["S0028390825004903"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110782","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An industrial perspective on ligand bias in GPCR drug discovery","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110782"}}